Alfresa Holdings Corporation
Tanabe Seiyaku Co., Ltd.

Launch of “Modiodal® Tablets 100mg” for the Treatment of Narcolepsy

Alfresa Pharma Corporation, a wholly-owned subsidiary of Alfresa Holdings Corporation, and Tanabe Seiyaku Co., Ltd. announced today the launch of the co-marketing product, Modiodal® Tablets 100mg (generic name: modafinil), of which approval holder is Alfresa Pharma, for excessive daytime sleepiness associated with narcolepsy on March 28, 2007.

Narcolepsy is chronic, neurologic sleep disorder characterized by uncontrollable sleep attacks at any time and in any place, caused by excessive sleepiness. It leads to inability or difficulty to perform daily activities, and sometimes to unexpected accidents. Nationwide, narcolepsy patients, exactly diagnosed and treated by narcolepsy specialists, are estimated to be approximately 2,000 people.

Products containing modafinil are currently marketed in over 30 countries, mainly in U.S. and Europe. It has been used as the first-line treatment for excessive daytime sleepiness associated with narcolepsy.

The companies believe that “Modiodal® Tablets 100mg” makes great contribution to the treatment of narcolepsy symptom.

The companies are conducting co-development for further indication for residual sleepiness associated with obstructive sleep apnea syndrome.

Contact for further information about this press release:
Pharmaceuticals Marketing
Alfresa Pharma Corporation
2-2-9 Kokumachi, Chuo-ku, Osaka 540-8575, Japan
Phone : +81-6-6941-0306, Fax : +81-6-6943-8212

Corporate Communications Division
TANABE SEIYAKU CO., LTD.
3-2-10, Doshomachi, Chuo-ku, Osaka 541-8505, JAPAN
Phone : +81-6-6205-5211, Fax : +81-6-6205-5105